Screening method for cancer treatment drugs, immunostimulants and anticancer substances
A cancer treatment drug combining apolipoprotein and interferon regulatory factor 7 with T cell co-stimulatory factors addresses HVJ-E's limitations, inducing systemic antitumor effects on both target and non-target cancer tissues.
Patent Information
- Application Number
- JP2022550581
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-09-16
- Filing Date
- 2021-09-15
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2041-09-15
AI Technical Summary
Existing cancer treatments using viral therapies like HVJ-E face challenges such as limited efficacy on non-target tumors, antibody generation, stability issues, and safety concerns, while apolipoprotein and interferon regulatory factor 7's antitumor effects are not fully understood.
Development of a cancer treatment drug containing apolipoprotein and/or interferon regulatory factor 7, combined with T cell co-stimulatory factors, to induce systemic antitumor effects and enhance immune response in both target and non-target cancer tissues.
The drug achieves antitumor effects comparable to HVJ-E administration, with enhanced immune activation and T cell migration to distant lesions, providing broad cancer treatment efficacy.
Smart Images

Figure 0007590010000004 
Figure 0007590010000005 
Figure 0007590010000006
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for screening drugs for treating cancer, immunostimulants, and anticancer substances. [Background technology]
[0002] Immunotherapy in cancer treatment has recently been attracting attention due to the development of immune checkpoint inhibitor therapy and CAR-T cell therapy. The basic concept is to maintain the activity of killer T cells against cancer cells and ensure their numbers. However, there are many cases of non-response to immune checkpoint inhibitor therapy. CAR-T cell therapy depends on the specificity of the antibody used, and tumor antigens are limited to one type. However, cancers have different combinations of neoantigens for each case and also have intratumoral heterogeneity. Therefore, it is thought that active induction of antitumor immunity in the body would be an effective cancer treatment, but such a therapy has not yet been developed.
[0003] Viral therapy such as T-VEC, which is a herpes simplex virus (HSV) loaded with the cytokine GM-CSF that activates dendritic cells, has attracted attention as a new tumor treatment. T-VEC has been approved by the FDA as a treatment for melanoma. T-VEC has tumor lytic properties, and it was expected that it would induce a systemic antitumor effect by enhancing its antigen presentation ability with GM-CSF, but in reality, its antitumor effect against non-target tumors was limited.
[0004] The hemagglutinating virus of Japan envelope (hereinafter referred to as "HVJ-E") is a particle of the hemagglutinating virus of Japan (HVJ) that has been completely inactivated and purified, leaving only the cell membrane fusion ability of the outer membrane. Unlike conventional oncolytic viruses, HVJ-E is non-proliferative and therefore highly safe, and induces an antitumor effect by activating the immune system (Non-Patent Document 1). In a phase I / IIa clinical trial of HVJ-E for stage IIIC and IV melanoma cases, an antitumor effect was observed in three out of six target tumor sites (Non-Patent Document 2). In a phase I clinical trial, intratumoral administration of HVJ-E demonstrated a remarkable antitumor effect, and 66.6% of cases achieved a partial response (PR) according to RECIST, which included the assessment of tumor size at the administration site and non-administration site. Phase I clinical trials were also conducted on cases of castration-resistant recurrent prostate cancer and malignant pleural mesothelioma, and it was found that 5 out of 6 cases of prostate cancer administered high-dose HVJ-E developed stable disease (SD) (Non-Patent Document 3), while 3 out of 3 cases of malignant pleural mesothelioma developed SD. This demonstrated that HVJ-E has a high antitumor effect in actual cancer patients.
[0005] Virotherapy is expected to be a cancer treatment with a new mechanism, but the molecular mechanism of why virotherapy has such a high antitumor effect is largely unknown. In addition, virotherapy has various problems, such as the high hurdle of using viruses as drugs in general hospitals, the difficulty of supplying viruses as drugs in large quantities and stably, and the difficulty of frequent administration because antibodies are produced against the virus.
[0006] On the other hand, HVJ-E is a virus that has lost its ability to proliferate, making it safer than other viral therapies, but like other viral therapies, it produces antibodies against HVJ itself. In addition, HVJ has the problem of the risk of developing thrombus due to its ability to agglutinate red blood cells. Furthermore, HVJ-E exerts a tumor-suppressing effect at the site where it is directly administered, but its tumor-suppressing effect at non-administered sites (remote sites) is limited.
[0007] Concerning the antitumor effects of apolipoproteins, the antitumor effect of ApoA1 is disclosed in Patent Document 1 and Non-Patent Document 4. However, the data on which this is based shows that administration of large amounts of ApoA1 extracted from human plasma to mutant mice lacking ApoA1 was able to inhibit the engraftment of cancer cells, and does not confirm the antitumor effect of ApoA1 against tumors in wild-type mice in which ApoA1 is originally present in the plasma. [Prior art documents] [Patent documents]
[0008] [Patent Document 1] US 2011 / 0305707 A1 [Non-patent literature]
[0009] [Non-Patent Document 1] Kurooka et al., Cancer Res January 1 2007 67 (1) 227-236 [Non-Patent Document 2] Kiyohara et al. Cancer Immunology, Immunotherapy 2020 69, 1131-1140 [Non-Patent Document 3] Fujita et al. Cancer science 2020 111: 1692-1698 [Non-Patent Document 4] Zamanian-Daryoush et al. J Biol Chem. 2013 288(29):21237-21252 Summary of the Invention [Problem to be solved by the invention]
[0010] The present invention aims to elucidate the molecular mechanism of the antitumor effect of HVJ-E, and to provide a cancer treatment drug that can achieve the same antitumor effect as that achieved by administration of HVJ-E without administration of HVJ-E, and a cancer treatment drug that exhibits an anticancer effect even against cancer tissues located at sites distant from the cancer tissue to be treated. Another objective of the present invention is to provide an immunostimulant that is effective in treating diseases other than cancer by activating the immunity at the site of a distant lesion. Another objective of the present invention is to provide a method for screening an anticancer substance that can achieve the same antitumor effect as that of HVJ-E without administration of HVJ-E. [Means for solving the problem]
[0011] In order to solve the above problems, the present invention includes the following inventions. [1] A drug for cancer treatment that contains as an active ingredient a gene product whose expression is increased in cancer cells administered with HVJ-E. [2] The pharmaceutical composition for cancer treatment according to [1] above, wherein the active ingredient is an apolipoprotein and / or interferon regulatory factor 7. [3] The pharmaceutical composition for cancer treatment according to [1] or [2] above, which is used in combination with a T cell costimulatory factor agonist. [4] A drug for cancer treatment that uses a combination of HVJ-E and a T cell costimulatory factor agonist. [5] The pharmaceutical composition for use in cancer treatment according to [3] or [4] above, further comprising a CD4-positive T cell depleting antibody. [6] An immunostimulant using at least one selected from the group consisting of apolipoproteins, interferon regulatory factor 7, and HVJ-E in combination with a T-cell costimulatory factor agonist. [7] The immunostimulant described in [6] above, which is for local administration. [8] The immunostimulant according to [6] or [7] above, further comprising a CD4-positive T cell depleting antibody. [9] A method for screening an anticancer substance, comprising the steps of: (1) contacting a test substance with cancer cells; (2) measuring the expression level of IRF7 in the cancer cells; and (3) comparing the obtained IRF7 expression level with the IRF7 expression level of the cancer cells not contacted with the test substance to select a test substance that increases the expression level. The method according to claim 1, further comprising:
[10] A method for screening an anticancer substance, comprising the steps of: (1) contacting a test substance with cancer cells; (2) measuring the expression level of apolipoprotein in the cancer cells; and (3) comparing the obtained apolipoprotein expression level with the apolipoprotein expression level in the cancer cells not in contact with the test substance, and selecting a test substance that increases the expression level. The method according to claim 1, further comprising: Effect of the Invention
[0012] The present invention can provide a cancer therapeutic agent that has an antitumor effect equivalent to that of HVJ-E administration, and a cancer therapeutic agent that has an antitumor effect on non-target cancer tissues that are located at sites distant from the target cancer tissues to which the cancer therapeutic agent is directly administered and that are not directly administered. The present invention can also provide an immunostimulant that can migrate T cells induced at a local lesion site to a distant lesion site. Furthermore, the screening method of the present invention can screen for an anticancer substance that has an antitumor effect equivalent to that of HVJ-E administration. [Brief description of the drawings]
[0013] [Figure 1]This figure shows the results of transplanting tumor tissue from a melanoma patient into NOD-SCID mice to form tumors, administering HVJ-E or PBS into the tumor, and recording the tumor volume. (A) shows the result of transplanting tumor tissue from the first patient, and (B) shows the result of transplanting tumor tissue from the second patient. [Diagram 2] B16F10 cells (mouse melanoma cells) were transplanted into SCID mice and NSG mice to form tumors, and HVJ-E or PBS was administered into the tumor, and the tumor volume was recorded. (A) shows the results for SCID mice, and (B) shows the results for NSG mice. [Diagram 3] B16F10 cells were transplanted into GFP mice to form tumors, HVJ-E or PBS was administered intratumorally, the tumors were then excised, and the genes whose expression was increased by HVJ-E administration were analyzed. [Figure 4] FIG. 1 shows the results of transplanting Irf7-deficient B16F10 cells into C57BL / 6N mice to form tumors, administering HVJ-E or PBS into the tumor, and recording the tumor volume. [Diagram 5] FIG. 1 shows the results of transplanting Apod-deficient B16F10 cells into C57BL / 6N mice to form tumors, administering HVJ-E or PBS into the tumor, and recording the tumor volume. [Figure 6] Tumor tissue from a melanoma patient was transplanted into NOD-SCID mice to form tumors, and HVJ-E or PBS was administered intratumorally to record the tumor volume (see Figure 1). The tumors were then excised from the mice, and the genes whose expression was increased by HVJ-E administration were analyzed. [Figure 7] FIG. 1 shows the results of transplanting Tet GFP-Irf7- or Tet GFP-introduced B16F10 cells into C57BL / 6N mice to form tumors, and recording the tumor volume in mice administered or not administered doxycycline. (A) shows the results for the Tet GFP group, and (B) shows the results for the Tet GFP-Irf7 group. [Figure 8]B16F10 cells transfected with Tet GFP-Apod, Tet GFP-Apol9a, or Tet GFP-Apol9a-Apol9b-Apod were transplanted into C57BL / 6N mice to form tumors, and the tumor volumes were recorded with or without doxycycline administration. (A) shows the results for the Tet GFP-Apod group, (B) shows the results for the Tet GFP-Apol9a group, and (C) shows the results for the Tet GFP-Apol9a-Apol9b-Apod group. [Figure 9] This figure shows the results of transplanting B16F10 cells (wild type) into C57BL / 6N mice to form tumors, administering a mixed solution of three types of recombinant proteins, apolipoprotein D, L9a, and L9b, or solvent into the tumor, and recording the tumor volume. [Figure 10] B16F10 cells (wild type) were transplanted into both the left and right sides of C57BL / 6N mice to form tumors, and HVJ-E and OX40 agonist antibody (HVJ-E+OX40 group), HVJ-E and control IgG (HVJ-E+CtrlIgG group), OX40 agonist antibody only (OX40 group), or control IgG only (CtrlIgG group) were administered into the tumor on the left side. The tumor volumes of the target tumor (left) and non-target tumor (right) were recorded, and the results are shown in the figure. (A) is a schematic diagram of a tumor-bearing mouse, (B) is the result for the target tumor, and (C) is the result for the non-target tumor. [Figure 11] CT26 cells (wild type) were transplanted into both the left and right sides of C57BL / 6N mice to form tumors, and HVJ-E and OX40 agonist antibody (HVJ-E+OX40 group), HVJ-E and control IgG (HVJ-E+CtrlIgG group), OX40 agonist antibody only (OX40 group), or control IgG only (CtrlIgG group) were administered into the tumor on the left side. The tumor volumes of the target tumor (left) and non-target tumor (right) were recorded, and the results are shown in the figure. (A) is a schematic diagram of a tumor-bearing mouse, (B) is the result for the target tumor, and (C) is the result for the non-target tumor. [Figure 12]MC38 cells (wild type) were transplanted into both the left and right sides of C57BL / 6N mice to form tumors, and HVJ-E and OX40 agonist antibody (HVJ-E+OX40 group), HVJ-E and control IgG (HVJ-E+CtrlIgG group), OX40 agonist antibody only (OX40 group), or control IgG only (CtrlIgG group) were administered into the tumor on the left side. The tumor volumes of the target tumor (left) and non-target tumor (right) were recorded, and the results are shown in the figure. (A) is a schematic diagram of a tumor-bearing mouse, (B) is the result for the target tumor, and (C) is the result for the non-target tumor. [Figure 13] B16F10 cells (wild type) were transplanted into both the left and right sides of SCID mice to form tumors, and HVJ-E and OX40 agonist antibody (HVJ-E+OX40 group), HVJ-E and control IgG (HVJ-E+CtrlIgG group), OX40 agonist antibody only (OX40 group), or control IgG only (CtrlIgG group) were administered into the tumor on the left side. The tumor volumes of the target tumor (left) and non-target tumor (right) were recorded, and the results are shown in the figure. (A) is a schematic diagram of a tumor-bearing mouse, (B) is the result for the target tumor, and (C) is the result for the non-target tumor. [Figure 14] B16F10 cells (wild type) were transplanted into both the left and right sides of C57BL / 6N mice to form tumors, and HVJ-E and the immune checkpoint inhibitor anti-PD-1 antibody (HVJ-E+PD-1 group), HVJ-E and control IgG (HVJ-E+CtrlIgG group), anti-PD-1 antibody only (PD-1 group), or control IgG only (CtrlIgG group) were administered into the tumor on the left side. The tumor volumes of the target tumor (left) and non-target tumor (right) were recorded, and the results are shown in the figure. (A) is a schematic diagram of a tumor-bearing mouse, (B) is the result for the target tumor, and (C) is the result for the non-target tumor. [Figure 15]B16F10 cells (wild type) were transplanted into both the left and right sides of C57BL / 6N mice to form tumors, and HVJ-E and 4-1-BB agonist antibody (HVJ-E+4-1-BB group), HVJ-E and control IgG (HVJ-E+CtrlIgG group), 4-1-BB agonist antibody only (4-1-BB group), or control IgG only (CtrlIgG group) were administered into the tumor on the left side. The tumor volumes of the target tumor (left) and non-target tumor (right) were recorded, and the results are shown in the figure. (A) is a schematic diagram of a tumor-bearing mouse, (B) is the result for the target tumor, and (C) is the result for the non-target tumor. [Figure 16] B16F10 cells (wild type) were transplanted into the left side of C57BL / 6N mice, and mouse lung adenocarcinoma LL / 2 cells were transplanted into the right side to form tumors. HVJ-E and OX40 agonist antibody (HVJ-E+OX40 group), HVJ-E and control IgG (HVJ-E+CtrlIgG group), OX40 agonist antibody only (OX40 group), or control IgG only (CtrlIgG group) were administered into the tumor on the left side, and the tumor volumes of the target tumor (left) and non-target tumor (right) were recorded. (A) is a schematic diagram of a tumor-bearing mouse, (B) is the result for the target tumor, and (C) is the result for the non-target tumor. [Figure 17] B16F10 cells (wild type) were transplanted into both the left and right sides of C57BL / 6N mice to form tumors, and HVJ-E and OX40 agonist antibodies were administered into the tumor on the left side, and antibodies to eliminate CD4-positive T cells (HVJ-E+OX40 group+CD4 group), antibodies to eliminate CD8-positive T cells (HVJ-E+OX40 group+CD8 group), or control IgG (HVJ-E+OX40 group+Ctrl group) were administered intraperitoneally. The tumor volumes of the target tumor (left) and non-target tumor (right) were recorded. (A) is a schematic diagram of a tumor-bearing mouse, (B) is the result for the target tumor, and (C) is the result for the non-target tumor. [Figure 18]B16F10 cells transfected with Tet GFP-Apol9a-Apol9b-Apod were transplanted into the left side of C57BL / 6N mice, and B16F10 cells (wild type) were transplanted into the right side to form tumors. Doxycycline was administered, and OX40 agonist antibody or control IgG was administered into the tumor on the left side. The tumor volumes of the target tumor (left) and non-target tumor (right) were recorded. (A) is a schematic diagram of the tumor-bearing mice, (B) is the result for body weight, (C) is the result for the target tumor, and (D) is the result for the non-target tumor. [Figure 19] B16F10 cells transfected with Tet GFP-Irf7 were transplanted into the left side of C57BL / 6N mice, and B16F10 cells (wild type) were transplanted into the right side to form tumors. Doxycycline was administered, and OX40 agonist antibody or control IgG was administered into the tumor on the left side. The tumor volumes of the target tumor (left) and non-target tumor (right) were recorded. (A) is a schematic diagram of a tumor-bearing mouse, (B) is the result for the target tumor, and (C) is the result for the non-target tumor. [Figure 20] B16F10 cells transfected with Tet GFP were transplanted into the left side of C57BL / 6N mice, and B16F10 cells (wild type) were transplanted into the right side to form tumors. Doxycycline was then administered, and OX40 agonist antibody or control IgG was administered into the tumor on the left side. The tumor volumes of the target tumor (left) and non-target tumor (right) were recorded. (A) is a schematic diagram of a tumor-bearing mouse, (B) is the result for the target tumor, and (C) is the result for the non-target tumor. [Figure 21] B16F10 cells (wild type) were transplanted into both the left and right sides of C57BL / 6N mice to form tumors, and HVJ-E and OX40 agonist antibody (HVJ-E+OX40 group), HVJ-E and control IgG (HVJ-E+CtrlIgG group), PBS and OX40 agonist antibody (PBS+OX40 group), or PBS and control IgG (PBS+CtrlIgG group) were administered into the tumor on the left side. The figures show the results of measuring the number of CD4-positive T cells and CD8-positive T cells in the target tumor and non-target tumor. [Figure 22]FIG. 22 shows the results of measuring the expression levels of IFNγ and Ki67 by sorting CD4-positive T cells and CD8-positive T cells from non-target cells in the HVJE+OX40 group and the HVJE+CtrlIgG group in FIG. 21. [Diagram 23] B16F10 cells transfected with Tet GFP-Apol9a-Apol9b-Apod were transplanted into the left side of C57BL / 6N mice, and B16F10 cells (wild type) were transplanted into the right side to form tumors. Doxycycline was administered, and OX40 agonist antibody or control IgG was administered into the tumor on the left side. CD4-positive T cells and CD8-positive T cells were separated from the target tumor and non-target tumor, and the expression levels of IFNγ, Ki67, granzymes A and B were measured. [Figure 24] B16F10 cells transfected with Tet GFP-Apod were transplanted into the left side of C57BL / 6N mice, and B16F10 cells (wild type) were transplanted into the right side to form tumors. Doxycycline was administered, and OX40 agonist antibody or control IgG was administered into the tumor on the left side. The tumor volumes of the target tumor (left) and non-target tumor (right) were recorded. (A) is a schematic diagram of a tumor-bearing mouse, (B) is the result for the target tumor, and (C) is the result for the non-target tumor. [Diagram 25] FIG. 25 shows the results of measuring the numbers of CD4-positive T cells and CD8-positive T cells in the target tumor and non-target tumor of the mouse in FIG. 24. [Figure 26] B16F10 cells (wild type) were transplanted into both the left and right sides of C57BL / 6N mice to form tumors, and Apod and OX40 agonist antibody (Apod / OX40 group), Apod and control IgG (Apod / CtrlIgG group), PBS and OX40 agonist antibody (PBS / OX40 group), or PBS and control IgG (PBS / CtrlIgG group) were administered into the tumor on the left side. The tumor volumes of the target tumor (left) and non-target tumor (right) were recorded, and the results are shown in the figure. (A) shows the results for the target tumor, and (B) shows the results for the non-target tumor. [Figure 27]FIG. 27 shows the results of measuring the numbers of CD4-positive T cells and CD8-positive T cells in the target tumor and non-target tumor of the mouse in FIG. 26. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] [Cancer treatment drugs] The present invention provides a pharmaceutical for cancer treatment, which contains as an active ingredient a gene product whose expression is increased in cancer cells administered with HVJ-E. The gene product whose expression is increased in cancer cells administered with HVJ-E can be determined using a known method. For example, a method may be used in which a cancer-bearing mouse is produced, RNA is extracted from tumors administered with HVJ-E and tumors not administered with HVJ-E, and expression is compared by sequence analysis. In the pharmaceutical of the present invention, apolipoprotein and interferon regulatory factor 7 can be suitably used as gene products whose expression is increased in cancer cells administered with HVJ-E.
[0015] The apolipoprotein as the active ingredient of the pharmaceutical of the present invention may be an apolipoprotein of any organism, but is preferably an apolipoprotein of a mammal. Examples of mammals include, but are not limited to, human, mouse, rat, cow, horse, pig, dog, cat, etc. Among them, it is particularly preferable to use a human apolipoprotein. Examples of human apolipoproteins include, but are not limited to, APOA1BP (also known as NAXE), APOOL, APOO, APOD, APOE, APOL1, APOL2, APOL3, APOL4, APOL5, APOL6, APOC1, APOC2, APOC4, etc. Preferred are APOD, APOL1, and APOL6. One type of apolipoprotein may be used as the active ingredient, or two or more types may be combined to be used as the active ingredient. The amino acid sequence of human apolipoprotein and the nucleotide sequence of the gene encoding it can be obtained from a known database such as NCBI. Examples of the amino acid sequence and nucleotide sequence of the gene encoding the apolipoprotein include, but are not limited to, the amino acid sequence and nucleotide sequence listed in Table 1.
[0016] [Table 1]
[0017] The pharmaceutical of the present invention, which has an apolipoprotein as an active ingredient, may be a pharmaceutical containing a recombinant apolipoprotein as an active ingredient. When a recombinant apolipoprotein is used as an active ingredient, the pharmaceutical of the present invention may be formulated together with a pharma- ceutical acceptable carrier. The recombinant apolipoprotein can be produced by appropriately using known gene recombination techniques. For example, the recombinant apolipoprotein can be produced by preparing an expression vector into which DNA encoding the apolipoprotein is inserted, introducing the expression vector into a suitable host cell to express the apolipoprotein, and purifying the expression vector by a known method.
[0018] The medicament of the present invention, which contains an apolipoprotein as an active ingredient, may contain, as an active ingredient, a nucleic acid that expresses the apolipoprotein in cancer cells after administration. When the medicament of the present invention contains a nucleic acid that expresses the apolipoprotein as an active ingredient, the medicament of the present invention may be in the form of a virus vector into which DNA encoding the apolipoprotein is inserted, a mammalian expression vector into which DNA encoding the apolipoprotein is inserted, mRNA of the apolipoprotein, a liposome in which the expression vector or mRNA is encapsulated, or the like.
[0019] Interferon regulatory factor 7 (hereinafter referred to as "IRF7") is one of the transcription factors that bind to the expression regulatory region of the interferon (IFN) β gene. The IRF7 as the active ingredient of the pharmaceutical of the present invention may be IRF7 from any organism, but mammalian IRF7 is preferred. Examples of mammalian organisms include, but are not limited to, human, mouse, rat, cow, horse, pig, dog, cat, etc. Among them, it is particularly preferred to use human IRF7. The human IRF7 gene is a gene located at 612555-615950 on chromosome 11 of GRCh38 / hg38. The amino acid sequence of human IRF7 and the nucleotide sequence of the gene encoding it can be obtained from a known database such as NCBI. Examples include, but are not limited to, the amino acid sequences and nucleotide sequences listed in Table 2.
[0020] [Table 2]
[0021] The pharmaceutical of the present invention, which contains IRF7 as an active ingredient, may be a pharmaceutical containing recombinant IRF7 protein as an active ingredient. When recombinant IRF7 protein is used as an active ingredient, the pharmaceutical of the present invention can be formulated together with a pharma- ceutically acceptable carrier. The recombinant IRF7 protein can be produced by appropriately using known gene recombination techniques. For example, it can be produced by preparing an expression vector into which DNA encoding the IRF7 protein is inserted, introducing the vector into an appropriate host cell to express the protein, and purifying the vector by a known method.
[0022] The medicament of the present invention, which contains IRF7 as an active ingredient, may contain, as an active ingredient, a nucleic acid that expresses IRF7 protein in cancer cells after administration. When the medicament of the present invention contains a nucleic acid that expresses IRF7 protein as an active ingredient, the medicament of the present invention may be in the form of a viral vector into which DNA encoding IRF7 protein has been inserted, a mammalian expression vector into which DNA encoding IRF7 protein has been inserted, IRF7 protein mRNA, a liposome in which the expression vector or mRNA has been encapsulated, or the like.
[0023] The pharmaceutical of the present invention may be administered as a single agent containing an apolipoprotein as an active ingredient, a single agent containing IRF7 as an active ingredient, or a combination agent containing an apolipoprotein and IRF7 as active ingredients. Also, a single agent containing an apolipoprotein as an active ingredient and a single agent containing IRF7 as an active ingredient may be used in combination.
[0024] The pharmaceutical of the present invention can be used in combination with a T cell costimulatory factor agonist. That is, the pharmaceutical of the present invention can be implemented as a combination drug containing an apolipoprotein and a T cell costimulatory factor agonist as active ingredients, a combination drug containing IRF7 and a T cell costimulatory factor agonist as active ingredients, or a combination drug containing an apolipoprotein, IRF7, and a T cell costimulatory factor agonist as active ingredients. In addition, a single agent containing an apolipoprotein as an active ingredient and a single agent containing a T cell costimulatory factor agonist may be used in combination, a single agent containing IRF7 as an active ingredient and a single agent containing a T cell costimulatory factor agonist may be used in combination, or a combination drug containing an apolipoprotein and IRF7 as active ingredients and a single agent containing a T cell costimulatory factor agonist may be used in combination.
[0025] By using the medicament of the present invention in combination with a T cell costimulatory factor agonist, it becomes possible to exert an anticancer effect on cancer tissues located at sites distant from the target cancer tissue. Specifically, for example, when the medicament of the present invention and a T cell costimulatory factor agonist are locally administered into a tumor, not only is the growth of the tumor to which the drug is administered (target tumor) suppressed, but also a growth-suppressing effect is exerted on tumors located at sites distant from the target tumor and to which nothing is administered (non-target tumor) (see Examples).
[0026] Examples of T cell costimulatory factors include OX40, 4-1BB, GITR, CD28, CD40, ICOS, HVEM, CD27, CD30, DR3, TNFR2, LTαβ, and LFA1. As the T cell costimulatory factor agonist, an agonist antibody of each T cell costimulatory factor or a ligand of each T cell costimulatory factor as exemplified above can be suitably used. Preferably, it is an agonist of OX40, 4-1BB, GITR, CD28, CD40, ICOS, or CD27. The agonist antibody of the T cell costimulatory factor may be a known antibody or a self-produced antibody. Ligands for each T cell costimulatory factor include OX40L / TNFSF4, 4-1-BB ligand / TNFSF9, GITR ligand / TNFSF18, CD80, CD86, ICOSLG, CD30L / TNFSF8, TL1A / TNFSF15, LIGHT / TNFSF14, TNFα, HVEM / TNFRSF14, LTBR, etc. The amino acid sequence of each ligand and the nucleotide sequence of the gene encoding it can be obtained from a known database such as NCBI. For example, the amino acid sequences and nucleotide sequences listed in Table 3 can be included, but are not limited to these.
[0027] [Table 3]
[0028] The T cell costimulatory factor agonist can be administered in the form of a formulation of the antibody or the recombinant protein of the ligand together with a pharma- ceutically acceptable carrier. The T cell costimulatory factor agonist can also be administered as a nucleic acid that expresses the ligand protein in cancer cells. When administered as a nucleic acid, it can be administered in the form of a virus vector into which DNA encoding the ligand protein is inserted, a mammalian expression vector into which DNA encoding the ligand protein is inserted, mRNA of the ligand protein, a liposome in which the expression vector or mRNA is encapsulated, or the like.
[0029] The pharmaceutical of the present invention may be a pharmaceutical using a combination of HVJ-E and a T cell costimulatory factor agonist instead of apolipoprotein and IRF7. HVJ-E can be prepared by inactivating HVJ. Examples of methods for inactivating HVJ to prepare the HVJ-E of the present invention include UV treatment and alkylation treatment. By inactivation treatment, the genomic RNA is denatured or fragmented within the viral envelope, losing its activity and losing its ability to replicate as a virus. Specifically, the HVJ-E of the present invention can be prepared according to the methods described in JP 2001-286282 A (WO01 / 57204 A), JP 2002-065278 A, WO03 / 014338 A, Kaneda et al. (Molecular Therapy 2002, 6, 2, 219-226), etc.
[0030] The route of administration of HVJ-E is not particularly limited, but it is preferable to inject it into the cancer tissue (tumor) or its surrounding area. The dosage can be appropriately determined by a doctor or medical professional, taking into consideration the size of the cancer tissue (tumor), the age, weight, condition, etc. of the patient. 3 Less than (e.g., 200 mm 3In the case of a tumor site with a single administration of HVJ-E, for example, the administration amount of HVJ-E per administration may be 3 Hemagglutinin Units (HAU) to 750,000 HAU, preferably 30 HAU to 300,000 HAU, more preferably 300 HAU to 200,000 HAU, and even more preferably 9,000 HAU to 100,000 HAU. Alternatively, it is preferably 100,000 HAU or less per kg of body weight.
[0031] The pharmaceutical of the present invention may be used in combination with a CD4-positive T cell depleting antibody in addition to the T cell costimulatory factor agonist. Examples of CD4-positive T cell depleting antibodies include humanized anti-CD4 antibodies "IT1208" (J Immunother Cancer. 2019 Jul 24; 7(1): 195. doi: 10.1186 / s40425-019-0677-y.), "MAX.16H5" (Front Immunol. 2019 May 24; 10: 1035. doi: 10.3389 / fimmu.2019.01035.), and "cM-T412" (J Clin Invest. 1997 May 1; 99(9): 2225-31. doi: 10.1172 / JCI119396.). By combining it with a CD4-positive T cell depleting antibody, the anti-cancer effect against non-target cancer tissue can be enhanced.
[0032] Cancers that can be treated by the pharmaceutical agent of the present invention are not particularly limited, and examples include melanoma (malignant melanoma), Merkel cell carcinoma, lung cancer, mesothelioma, head and neck cancer, esophageal cancer, gastric cancer, liver cancer, biliary tract cancer, pancreatic cancer, colorectal cancer, prostate cancer, kidney cancer, bladder cancer, urothelial cancer, breast cancer, uterine cancer, ovarian cancer, brain tumor, thyroid cancer, angiosarcoma, rhabdomyosarcoma, leiomyosarcoma, fibrosarcoma, synovial sarcoma, liposarcoma, neuroendocrine tumor, lymphoma, leukemia, and myeloma.
[0033] The pharmaceutical of the invention can be formulated according to conventional methods using a gene product whose expression is increased in cancer cells administered with HVJ-E as an active ingredient. For example, preparations for oral administration include solid or liquid dosage forms, specifically tablets (including sugar-coated tablets and film-coated tablets), pills, granules, powders, capsules (including soft capsules), syrups, emulsions, suspensions, and the like. These preparations are produced by known methods and contain carriers, diluents, or excipients that are commonly used in the pharmaceutical field. For example, lactose, starch, sucrose, magnesium stearate, and the like are used as carriers and excipients for tablets. Preparations for parenteral administration include, for example, injections and suppositories, and injections include dosage forms such as intravenous injections, subcutaneous injections, intradermal injections, intramuscular injections, drip injections, and intra-articular injections. Such injections are prepared according to known methods, for example, by dissolving, suspending, or emulsifying the above-mentioned active ingredient in a sterile aqueous or oily liquid that is commonly used for injections. As the aqueous liquid for injection, for example, physiological saline, isotonic liquid containing glucose and other auxiliary drugs, etc. are used, and may be used in combination with suitable solubilizing agents such as alcohol (e.g., ethanol, etc.), polyalcohol (e.g., propylene glycol, polyethylene glycol, etc.), nonionic surfactants (e.g., polysorbate 80, HCO-50, etc.). As the oily liquid, for example, sesame oil, soybean oil, etc. are used, and may be used in combination with benzyl benzoate, benzyl alcohol, etc. as solubilizing agents. Suppositories used for rectal administration are prepared by mixing the above-mentioned active ingredient with a normal suppository base. The preparations obtained in this way are safe and low-toxic, and therefore can be administered orally or parenterally to, for example, humans and mammals (e.g., rats, mice, rabbits, sheep, pigs, cows, cats, dogs, monkeys, etc.).
[0034] When the active ingredient of the pharmaceutical of the invention is a recombinant protein or an antibody, it is preferable to administer it as an injection or infusion formulated together with a pharma- ceutically acceptable carrier via a parenteral route, for example, intravenously, intramuscularly, intradermally, intraperitoneally, subcutaneously, or topically. The antibody may be a polyclonal or monoclonal antibody. It may also be a complete antibody molecule, or an antibody fragment (e.g., Fab, F(ab')2, Fab', Fv, scFv, etc.) capable of specifically binding to an antigen. The antibody is preferably a human chimeric antibody or a humanized antibody.
[0035] When the active ingredient of the pharmaceutical of the invention is a nucleic acid, it can be administered in the form of a non-viral vector or a viral vector. When it is administered in the form of a non-viral vector, it can be administered using a method of introducing a nucleic acid molecule using liposomes (liposome method, HVJ-liposome method, cationic liposome method, lipofection method, lipofectamine method, etc.), a microinjection method, a method of transferring a nucleic acid molecule into a cell together with a carrier (metal particles) using a gene gun, etc. When it is administered in the form of a viral vector, it is possible to express the active ingredient in a target cancer cell by introducing a DNA constructed to express a target protein into a DNA or RNA virus such as a detoxified retrovirus, lentivirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, pox virus, polio virus, Sindbis virus, Sendai virus, SV40, etc., and infecting the target cancer cell with this recombinant virus.
[0036] The pharmaceutical of the present invention may contain 0.001 to 50% by mass, preferably 0.01 to 10% by mass, and more preferably 0.1 to 1% by mass of the active ingredient. The dosage of the pharmaceutical of the present invention is appropriately determined by a doctor or medical practitioner, taking into consideration the type of cancer, the severity of the disease, the age, weight, sex, medical history, etc. of the patient. For an average human weighing about 65 to 70 kg, the dosage is preferably about 0.02 mg to 4000 mg per day, more preferably about 0.1 mg to 200 mg. The total dosage per day may be a single dose or a divided dose.
[0037] [Immunostimulants] The present inventors have found that administering any one of apolipoprotein, IRF7, and HVJ-E in combination with a T cell costimulatory factor agonist increases the number of T cells and activates T cells in cancer tissues (non-target cancer tissues) located at sites distant from the target cancer tissue. Specifically, it has been confirmed that the number of T cells increases in the non-target cancer tissues, and the expression of interferon gamma (hereinafter referred to as "IFNγ") and granzyme A are increased. Thus, the present invention provides an immunostimulatory agent using at least one selected from the group consisting of apolipoprotein, IRF7, and HVJ-E in combination with a T cell costimulatory factor agonist.
[0038] The immunostimulant of the present invention is preferably used as an immunostimulant for local administration. The immunostimulant of the present invention can not only induce T cells to a local lesion site by local administration, but also migrate the T cells induced at the local lesion site to a distant lesion site. Therefore, the immunostimulant of the present invention can be called an immunostimulant for promoting migration of T cells induced at a local lesion site to a distant lesion site, or a migration promoter of T cells induced at a local lesion site to a distant lesion site.
[0039] The immunostimulant of the present invention can be suitably used not only for the above-mentioned cancer treatment drugs, but also for the treatment of diseases in which the same lesion site is formed at a location distant from the target lesion site. For example, the immunostimulant of the present invention can be suitably used for the treatment of infectious diseases in which a distant infection focus is formed. Examples of such infectious diseases include contagious impetigo, necrotizing fasciitis, cellulitis, osteomyelitis, meningitis, intractable skin ulcers (diabetic ulcers, etc.), tuberculosis, tinea, sexually transmitted diseases, herpes (herpes labialis, genital herpes), and shingles.
[0040] The immunostimulant of the present invention can be produced and used in the same manner as the above-mentioned pharmaceutical of the present invention.
[0041] [Method of screening for anticancer substances] The present invention provides a method for screening anticancer substances. Substances selected by the screening method of the present invention are useful as candidates for active ingredients of pharmaceuticals for treating cancer.
[0042] The first embodiment of the screening method of the present invention may include the following steps. (1) contacting a test substance with cancer cells; (2) measuring the expression level of IRF7 in the cancer cells; and (3) comparing the obtained IRF7 expression level with the IRF7 expression level of the cancer cells not in contact with the test substance, and selecting a test substance that increases the expression level.
[0043] In step (1), a test substance is contacted with cancer cells. The test substance is not particularly limited, but examples thereof include nucleic acids, peptides, proteins, non-peptide compounds, synthetic compounds, fermentation products, cell extracts, cell culture supernatants, plant extracts, mammalian tissue extracts, and plasma. The test substance may be a novel substance or a known substance. These test substances may form salts, and the salts of the test substances may be salts with physiologically acceptable acids or bases.
[0044] The cancer cells are not particularly limited as long as they are the cancer cells that are the subject of treatment by the medicament of the present invention. The cancer cells may be established cell lines, primary cultured cells, or cells of biopsy tissue. The cancer cells may also be genetically engineered cells. For example, cancer cells into which a vector has been introduced in which a reporter gene has been fused downstream of a DNA fragment having IRF7 promoter activity, or cancer cells into which a reporter gene has been knocked into an endogenous IRF7 gene, can be preferably used.
[0045] As a DNA fragment having IRF7 promoter activity, a DNA fragment from -1123 to +575 of the IRF7 gene consisting of the base sequence shown in SEQ ID NO: 1 (J Biol Chem. 2005 Apr 1;280(13):12262-12270. doi: 10.1074 / jbc.M404260200.) can be used. The reporter gene is not particularly limited as long as it is a commonly used one, but it is preferable to use one that is stable and whose activity can be easily quantified. For example, genes encoding luciferase, β-galactosidase, β-glucuronidase, chloramphenicol acetyltransferase, alkaline phosphatase, peroxidase, green fluorescent protein (GFP), etc. can be mentioned.
[0046] The method of contacting the test substance with the cancer cells is not particularly limited. For example, when using cultured cells or cultured tissue, the test substance may be added to the culture medium. For example, when contacting the test substance with the cells in the living body of a non-human animal, the test substance may be administered systemically, such as orally, intravenously, or intraperitoneally, or administered locally to a target organ or target tissue. In addition, it is preferable to provide a control group that is not contacted with the test substance.
[0047] In step (2), the expression level of IRF7 in cancer cells contacted with the test substance is measured. The expression level of IRF7 may be measured by measuring the amount of IRF7 protein or the amount of IRF7 mRNA. When measuring the amount of protein, protein can be extracted from cancer cells by a known method and quantified by a known method for measuring protein amount. Examples of known methods for measuring protein amount include Western blot, EIA, ELISA, RIA, and a method using a protein measurement reagent. When measuring the amount of mRNA, RNA can be extracted from cells by a known method and quantified by a known method for measuring mRNA amount. Examples of known methods for measuring mRNA amount include Northern blot, RT-PCR, quantitative RT-PCR, and RNase protection assay.
[0048] When a cancer cell is used in which a vector in which a reporter gene is fused downstream of a DNA fragment having IRF7 promoter activity is introduced, the expression level of IRF7 can be measured as the expression level of the reporter gene. The expression level of the reporter gene is appropriately selected depending on the protein (reporter gene product) encoded by the reporter gene. For example, when the reporter gene encodes luciferase, a cell lysate is prepared, and luciferin, which serves as a substrate, is added to the supernatant of the cell lysate, and the amount of luminescence is measured using a commercially available detector to determine the expression level of the reporter gene. When other reporter genes are used, the amount of the reporter gene product can also be measured by a known method.
[0049] In step (3), the IRF7 expression level obtained in step (2) is compared with the IRF7 expression level of cancer cells not contacted with the test substance, and a test substance that increases the expression level is selected. That is, if the IRF7 protein amount or mRNA amount or reporter gene expression level increases when the test substance is contacted, compared with the IRF7 protein amount or mRNA amount or reporter gene expression level in a control group not contacted with the test substance, the test substance can be selected as a target substance. The degree to which the test substance increases the IRF7 expression level is not particularly limited, and for example, a test substance that increases the IRF7 expression level by 1.5 times or more, 1.6 times or more, 1.7 times or more, 1.8 times or more, 1.9 times or more, or 2 times or more compared to the IRF7 expression level of cells not contacted with the test substance may be selected.
[0050] The second embodiment of the screening method of the present invention may include the following steps. (1) contacting a test substance with cancer cells; (2) measuring the expression level of apolipoprotein in the cancer cells; and (3) comparing the obtained apolipoprotein expression level with the apolipoprotein expression level in the cancer cells not in contact with the test substance, and selecting a test substance that increases the expression level.
[0051] The second embodiment can be carried out in the same manner as the first embodiment, except that IRF7 in the first embodiment is replaced with an apolipoprotein. Therefore, detailed explanations of each step of the second embodiment will be omitted.
[0052] There are several types of apolipoproteins, and the screening method of the present invention can measure the expression level of any one of apolipoproteins. The apolipoproteins whose expression levels are measured can be selected from, for example, APOA1BP, APOOL, APOO, APOD, APOE, APOL1, APOL2, APOL3, APOL4, APOL6, APOC1, APOC2, APOC4, etc.
[0053] When using cancer cells into which a reporter gene has been introduced, it is possible to use cancer cells into which a vector in which a reporter gene has been fused downstream of a DNA fragment having promoter activity of the apolipoprotein species to be measured has been introduced, or cancer cells into which a reporter gene has been knocked into an endogenous apolipoprotein gene. For example, as a DNA fragment having promoter activity of APOD, a DNA fragment of -817 to +64 of the APOD gene consisting of the base sequence shown in SEQ ID NO: 2 (Mol Neurobiol. 2013 Dec;48(3):669-680. doi: 10.1007 / s12035-013-8456-0.) or the like can be used.
[0054] The present invention includes the following inventions. (a-1) A method for treating cancer, comprising administering to a mammal an effective amount of a gene product whose expression is increased in cancer cells administered with a Sendai virus envelope. (a-2) A gene product whose expression is increased in cancer cells administered with a Sendai virus envelope for use in cancer treatment. (a-3) Use of a gene product whose expression is increased in cancer cells administered with a Sendai virus envelope for the manufacture of a pharmaceutical for treating cancer. In the invention (a-1), (a-2) or (a-3), the active ingredient may be an apolipoprotein and / or an interferon regulatory factor 7. In the invention (a-1), (a-2) or (a-3), a T cell costimulatory factor agonist may be used in combination.
[0055] (b-1) A method for treating cancer, comprising administering to a mammal an effective amount of a Sendai virus envelope and an effective amount of a T cell costimulatory factor agonist. (b-2) A T cell costimulatory factor agonist for use in cancer therapy in combination with Sendai virus envelope. (b-3) Sendai virus envelope for use in cancer treatment in combination with T cell costimulatory factor agonists. (b-4) Use of a T cell costimulatory factor agonist for the manufacture of a cancer therapeutic medicament for use in combination with a Sendai virus envelope. (b-5) Use of a Sendai virus envelope for the manufacture of a medicament for treating cancer to be used in combination with a T cell costimulatory factor agonist. (c-1) A method for immunostimulation, comprising administering to a mammal an effective amount of at least one selected from the group consisting of an apolipoprotein, interferon regulatory factor 7, and Sendai virus envelope, and an effective amount of a T cell costimulatory factor agonist. (c-2) Use of a combination of at least one selected from the group consisting of apolipoproteins, interferon regulatory factor 7, and Sendai virus envelope with a T cell costimulatory factor agonist to stimulate immunity. (c-3) Use of a T cell costimulatory factor agonist for producing an immunostimulatory agent for use in combination with at least one selected from the group consisting of apolipoproteins, interferon regulatory factor 7, and Sendai virus envelope. (c-4) Use of at least one member selected from the group consisting of apolipoproteins, interferon regulatory factor 7, and Sendai virus envelope for the manufacture of an immunostimulatory agent for use in combination with a T cell costimulatory factor agonist. EXAMPLES
[0056] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these.
[0057] [Experimental Method] Tumor formation The cancer cells used were B16F10 (mouse melanoma cell line), LL / 2 (mouse lung cancer cell line), MC38 (mouse colon cancer cell line), and CT26 (mouse colon cancer cell line). The culture medium for B16F10, LL / 2, and MC38 was DMEM containing 10% FBS, 100 U / mL penicillin, and 0.1 mg / mL streptomycin, and the culture medium for CT26 was RPMI containing 10% FBS, 100 U / mL penicillin, and 0.1 mg / mL streptomycin. All cells were cultured at 37°C with 5% CO2. After confirming that they were mycoplasma-negative, 5×10 5 The cancer cells were intradermally transplanted into mice at 0.05 μL / 50 μL PBS / mouse. Tumor formation was confirmed 5 to 7 days after the cancer cells were transplanted, and the day when tumor formation was confirmed was designated as Day 0, at which the experiment was started. Tumor diameter was measured every 2 days from Day 0. Tumor volume was calculated using the formula: [tumor volume = major axis x minor axis x minor axis x 1 / 2].
[0058] HVJ-E production and administration HVJ-E was prepared by the method described by Kaneda et al. (Molecular Therapy 2002, 6, 2, 219-226). HVJ-E inactivated with UV was centrifuged at 4°C, 15,000 rpm for 10 min, the supernatant was discarded, and the resulting solution was resuspended in PBS. HVJ-E was administered into the tumor at 2000HAU HVJ-E / 50μL on days 0, 2, and 4, a total of three times (excluding the PDX experiment).
[0059] Cell preparation Tet-expressing cells were generated by introducing the DNA sequences of Tet GFP, Tet GFP-Irf7, Tet GFP-Apod, Tet GFP-Apol9a, and Tet GFP-Apol9a-Apol9b-Apod into the ROSA region of B16F10 cells using the CRISPR / Cas9 system. Both Irf7-deficient and Apod-deficient B16F10 cells were generated using the CRISPR / Cas9 system.
[0060] Doxycycline administration Doxycycline hydrochloride dissolved in ultrapure water at 2 mg / mL was given to the mice as drinking water from the day before the experiment started (Day -1) until Day 6, and normal water was given to the mice from Day 7 onwards. Separately, 200 μL of 2 mg / mL doxycycline solution was orally administered to the mice using a probe every day from the day before the experiment started (Day -1) until Day 6, and on Days 8, 10 and 12.
[0061] Recombinant Proteins Expression plasmids for Apod, Apol9a, and Apol9b were introduced into Expi293F Cells (Thermo Fisher) using the ExpiFectamine 293 Transfection Kit (Thermo Fisher). The culture supernatant was filtered through Millex GV Low protein Binding 0.22 μm (Merck Millipore) and purified using AKTA pure 25 M1 (Cytiva). First, the protein was purified by Hitrap DEAE FF (Cytiva, 17-5055-01) with Start Buffer: 20mM Tris pH8.0 and Elution Buffer: 20mM Tris, 0.5M NaCl pH8.0. The fraction containing the target protein was purified by HisTrap HP (Cytiva, 17-5247-01) with Start Buffer: 20mM Sodium phosphate, 0.5M NaCl, 20mM imidazole pH7.4 and Elution Buffer: 20mM Sodium phosphate, 0.5M NaCl, 500mM imidazole pH7.4. The purified protein solution was replaced with PBS using a Hitrap Desalting column (Cytiva, 17-1408-01). A mixed solution of the three types of recombinant proteins (mass ratio = 1:1:1) was prepared and administered into the tumor at 35 μg / 80 μL per administration.
[0062] antibody The antibodies administered intratumorally were Ultra-LEAF Purified anti-mouse CD134 (OX-40) clone: OX-86 (Biolegend 119431) and InVivoMAb anti-mouse 4-1BB (CD137) clone LOB12.3 (BioXCell BE0169), which are agonistic antibodies against the T cell costimulatory factor OX40. The antibodies were administered intratumorally as 2000HAU HVJ-E + antibody 10μg / 50μL PBS. The anti-CD4 antibody used to remove CD4 positive T cells was InVivoMAb anti-mouse CD4 clone GK1.5 (BioXCell BE0003-1), and the anti-CD8 antibody used to remove CD8 positive T cells was InVivoMAb anti-mouse CD8α(2.43) clone LOB12.3 (BioXCell BE0061). These antibodies were administered intraperitoneally on days -1, 0, 2, 4, and 6. The dose of anti-CD4 antibody was 500 μg / 200 μL per administration, and the dose of anti-CD8 antibody was 100 μg / 200 μL per administration.
[0063] [Reference Example 1: Examination of the antitumor effect of HVJ-E on tumors formed in immunodeficient mice] (1) Antitumor effect of HVJ-E in immunodeficient mice implanted with melanoma patient tumor tissue Tumor tissues were collected from two melanoma patients who gave informed consent, and each was transplanted into NOD-SCID mice (PDX: Patient-derived xenografts). The day when tumor tissue engraftment was confirmed was set as Day 0. HVJ-E (2000HAU HVJ-E / 50μL PBS) was administered intratumorally once every two days from Day 0 to Day 42 in the first case (PDX1), and from Day 0 to Day 38 in the second case (PDX2). The tumor diameter was measured (tumor volume was recorded). The results are shown in Figure 1. (A) shows the results of the NOD-SCID mouse transplanted with the tumor tissue of the first patient, and (B) shows the results of the NOD-SCID mouse transplanted with the tumor tissue of the second patient. HVJ-E showed an inhibitory effect on tumor growth in both PDXs.
[0064] (2) Antitumor effect of HVJ-E in immunodeficient mice implanted with mouse melanoma cells B16F10 cells were transplanted into SCID mice and NSG mice, respectively, and tumors were allowed to form. HVJ-E was administered into the tumor on days 0, 2, and 4, and the tumor volume was recorded every two days from day 0 to day 14. The results are shown in Figure 2. (A) shows the results for SCID mice, and (B) shows the results for NSG mice. HVJ-E exhibited an inhibitory effect on tumor growth in both types of immunodeficient mice.
[0065] (3) Summary SCID mice are immunodeficient mice lacking T and B cells. NOD-SCID mice are immunodeficient mice lacking T and B cells and with low NK cell activity. NSG mice are severely immunodeficient mice lacking T, B and NK cells. These results demonstrated that at least T, B and NK cells are not essential for the antitumor effect of HVJ-E against target tumors.
[0066] [Example 1: Analysis of genes whose expression is increased by HVJ-E administration (1)] B16F10 cells were transplanted into GFP mice to form tumors. On days 0, 2, and 4, 2000HAU of HVJ-E / 50μL PBS was administered intratumorally to the HVJ-E-treated group, and 50μL of PBS was administered intratumorally to the control group. On day 5, the tumor was excised and GFP-negative cells were collected by FACS. RNA was extracted from the collected cells according to the standard method, and RNAseq was performed. The obtained sequence data was analyzed using STAR, Stringtie, and DESeq2, and illustrated using R. Genes whose expression was increased by HVJ-E administration are shown in Figure 3.
[0067] Example 2: Examination of the effect of HVJ-E on tumors formed by Irf7-deficient mouse melanoma cells Genes encoding transcription factors (Irf7, Batf2) were included among the genes whose expression was increased by HVJ-E administration (see Figure 3). Therefore, we created mouse melanoma cells lacking these genes and investigated the effects of these transcription factors on the antitumor effect of HVJ-E.
[0068] Irf7-deficient B16F10 cells were transplanted into C57BL / 6N mice to form tumors. On days 0, 2, and 4, HVJ-E was administered into the HVJ-E-treated group, and PBS was administered into the control group. Tumor volumes were recorded every two days from day 0 to day 14. The results are shown in Figure 4. No antitumor effect was observed when HVJ-E was administered to tumors formed by Irf7-deficient B16F10 cells. Although data are not shown, the antitumor effect of HVJ-E was maintained against tumors formed by Batf2-deficient B16F10 cells. These results demonstrated that the antitumor effect of HVJ-E requires increased expression of Irf7 in tumor tissues.
[0069] Example 3: Examination of the effect of HVJ-E on tumors formed by Apod-deficient mouse melanoma cells We investigated the genes whose expression was increased in an Irf7-dependent manner using Irf7-deficient cells and HVJ-resistant LL2 cells, and found that the expression of Apod, Apol9a, and Apol9b genes was increased. We then created mouse melanoma cells lacking the Apod gene and examined the effect of this on the antitumor effect of HVJ-E.
[0070] Apod-deficient B16F10 cells were transplanted into C57BL / 6N mice to form tumors. On days 0, 2, and 4, HVJ-E was administered into the tumors of the HVJ-E-treated group, and PBS was administered into the tumors of the control group. Tumor volumes were recorded every two days from day 0 to day 14. The results are shown in Figure 5. No antitumor effect was observed when HVJ-E was administered to tumors formed from mouse melanoma cells lacking the Apod gene.
[0071] [Example 4: Analysis of genes whose expression is increased by HVJ-E administration (2)] After the test in Reference Example 1(1) was completed, tumors were excised from NOD-SCID mice (PDX1, PDX2) transplanted with tumor tissue from melanoma patients, and mouse-derived cells were removed. RNA was extracted from the collected human-derived cells according to a standard method, and RNAseq was performed. The obtained sequence data was analyzed using STAR, Stringtie, and DESeq2, and illustrated using R.
[0072] The genes whose expression was increased by HVJ-E administration are shown in Figure 6. In human-derived tumors, as in mouse-derived tumors, increased expression of IRF7 was observed. Furthermore, the expression of apolipoproteins APOA1BP, APOOL, APOO, APOD, APOE, APOL1, APOL2, APOL3, APOL4, APOL6, APOC1, APOC2, and APOC4 was increased in both PDXs.
[0073] Example 5: Examination of the antitumor effect of Irf7 Increased expression of Irf7 was found in tumors administered with HVJ-E. However, no antitumor effect of HVJ-E was observed against tumors formed from Irf7-deficient mouse melanoma cells. Therefore, we investigated whether the expression of Irf7 in tumors would have an antitumor effect.
[0074] B16F10 cells transfected with Tet GFP-Irf7, which expresses GFP and Irf7 in a doxycycline-inducible manner, were transplanted into C57BL / 6N mice and allowed to form tumors (Tet GFP-Irf7 group). As a control, B16F10 cells transfected with Tet-GFP, which expresses only GFP in a doxycycline-inducible manner, were used to similarly allow tumors to form in mice (Tet GFP group). Both groups were further divided into doxycycline-treated and non-treated groups. The doxycycline administration schedule was as described above. Tumor volumes were recorded every 2 days from day 0 to day 14.
[0075] The results are shown in Figure 7. (A) shows the results for the Tet GFP group, and (B) shows the results for the Tet GFP-Irf7 group. Tumor growth was significantly suppressed by expressing Irf7 within the tumor.
[0076] Example 6: Examination of antitumor effects of apolipoproteins (1) Increased expression of apolipoproteins was found in tumors administered with HVJ-E. However, no antitumor effect of HVJ-E was observed against tumors formed from Apod-deficient mouse melanoma cells. Therefore, we investigated whether the expression of apolipoproteins in tumors would have an antitumor effect.
[0077] B16F10 cells transfected with Tet GFP-Apod, which expresses GFP and apolipoprotein D in a doxycycline-inducible manner, Tet GFP-Apol9a, which expresses GFP and apolipoprotein L9a in a doxycycline-inducible manner, and Tet GFP-Apol9a-Apol9b-Apod, which expresses GFP, apolipoprotein L9a, apolipoprotein L9b, and apolipoprotein D in a doxycycline-inducible manner, were transplanted into C57BL / 6N mice and allowed to form tumors (Tet GFP-Apod group, Tet GFP-Apol9a group, Tet GFP-Apol9a-Apol9b-Apod group). Each group was further divided into a doxycycline-treated group and a non-treated group. The doxycycline administration schedule was as described above. Tumor volumes were recorded every 2 days from day 0 to day 14.
[0078] The results are shown in Figure 8. (A) shows the results for the Tet GFP-Apod group, (B) shows the results for the Tet GFP-Apol9a group, and (C) shows the results for the Tet GFP-Apol9a-Apol9b-Apod group. In all groups, tumor growth was significantly suppressed when apolipoproteins were expressed in the tumor by administering doxycycline.
[0079] Example 7: Examination of antitumor effects of apolipoproteins (2) B16F10 cells (wild type) were transplanted into C57BL / 6N mice to form tumors. Mice were divided into two groups, an apolipoprotein group and a control group (vehicle). A mixed solution of three recombinant proteins, apolipoprotein D, L9a, and L9b (mass ratio = 1:1:1), was administered into the tumor of the apolipoprotein group seven times (35μg / 80μL / shot) on days 0, 2, 4, 6, 8, 10, and 12. The vehicle (80μL / shot) was administered into the tumor of the control group seven times.
[0080] The results are shown in FIG. 9. It was confirmed that tumor growth can be significantly suppressed by directly administering apolipoproteins into the tumor. In this example, a mixture of apolipoproteins D, L9a, and L9b was administered, but referring to the results of Example 6, it can be understood that the administration of apolipoproteins D, apolipoproteins L9a, or apolipoproteins L9b alone has a sufficient antitumor effect. Furthermore, these experimental results suggest that the apolipoproteins (APOA1BP, APOOL, APOO, APOD, APOE, APOL1, APOL2, APOL3, APOL4, APOL6, APOC1, APOC2, APOC4) whose expression was increased by the administration of HVJ-E in human-derived tumors also have an antitumor effect when used alone or in combination.
[0081] Example 8: Examination of systemic antitumor effects 8-1 Examination of the combined effect of HVJ-E and OX40 agonist antibody (1) Tumors formed by mouse melanoma B16F10 cells B16F10 cells (wild type) were transplanted into both the left and right sides of C57BL / 6N mice to form tumors. Four groups were established: a group administered HVJ-E and an agonist antibody against the T cell costimulator OX40 (HVJE+OX40 group), a group administered HVJ-E and control IgG (HVJE+CtrlIgG group), a group administered OX40 agonist antibody (OX40 group), and a group administered control IgG (CtrlIgG group). The dosage and administration schedule were as described above. The tumor was administered into the left tumor, and the volumes of the target tumor (left side) and non-target tumor (right side) were recorded every two days from Day 0 to Day 14 (see Figure 10(A)).
[0082] The results are shown in Figure 10 (B) and (C). (B) shows the results for the target tumor, and (C) shows the results for the non-target tumor. The HVJE+OX40 group and the HVJE+CtrlIgG group significantly suppressed the growth of the target tumor. On the other hand, the HVJE+OX40 group significantly suppressed the growth of the non-target tumor, but the HVJE+CtrlIgG group did not suppress the growth of the non-target tumor.
[0083] (2) Tumors formed by mouse colon cancer CT26 cells The experiment was performed in the same manner as in (1) above, except that B16F10 cells (wild type) were replaced with CT26 cells (wild type) (see Figure 11 (A)). The results are shown in Figure 11 (B) and (C). (B) shows the results for the target tumor, and (C) shows the results for the non-target tumor. The HVJE+OX40 group and the HVJE+CtrlIgG group significantly suppressed the growth of the target tumor. On the other hand, the HVJE+OX40 group significantly suppressed the growth of the non-target tumor, but the HVJE+CtrlIgG group did not suppress the growth of the non-target tumor.
[0084] (3) Tumors formed by mouse colon cancer MC38 cells The experiment was performed in the same manner as in (1) above, except that B16F10 cells (wild type) were replaced with MC38 cells (wild type) (see Figure 12 (A)). The results are shown in Figure 12 (B) and (C). (B) shows the results for the target tumor, and (C) shows the results for the non-target tumor. The HVJE+OX40 group and the HVJE+CtrlIgG group significantly suppressed the growth of the target tumor. On the other hand, the HVJE+OX40 group significantly suppressed the growth of the non-target tumor, but the HVJE+CtrlIgG group did not suppress the growth of the non-target tumor.
[0085] 8-2 Study on the combined effect of HVJ-E and anti-OX40 antibody on immunodeficient mice (SCID mice) The experiment was performed in the same manner as in 8-1(1) except that SCID mice were used instead of C57BL / 6N mice (see Figure 13(A)). The results are shown in Figure 13(B) and (C). (B) shows the results for target tumors, and (C) shows the results for non-target tumors. When SCID mice were used, the HVJE+OX40 group did not suppress the growth of non-target tumors. This result demonstrated that the anti-tumor effect on non-target tumors is lymphocyte-dependent.
[0086] 8-3 Examination of the combined effect of HVJ-E and anti-PD-1 antibody The experiment was performed in the same manner as in 8-1(1), except that anti-PD-1 antibody, an immune checkpoint inhibitor, was used instead of the OX40 agonist antibody (see FIG. 14(A)). The results are shown in FIG. 14(B) and (C). (B) shows the results for the target tumor, and (C) shows the results for the non-target tumor. The HVJE+PD-1 group did not suppress the growth of the non-target tumor.
[0087] 8-4 Study on the combined effect of HVJ-E and 4-1-BB agonist antibody The experiment was performed in the same manner as in 8-1(1), except that an agonist antibody against 4-1-BB, which is the same T cell costimulator as OX40, was used instead of the OX40 agonist antibody (see FIG. 15(A)). The results are shown in FIG. 15(B) and (C). (B) shows the results for the target tumor, and (C) shows the results for the non-target tumor. The HVJE+4-1-BB group significantly suppressed the growth of the non-target tumor. These results demonstrated that stimulation with HVJ-E and T cell costimulatory factors can induce a systemic antitumor effect.
[0088] Example 9: Examination of tumor cell tumor specificity in systemic antitumor effects To confirm whether the systemic antitumor effect is specific to the type of tumor cells, LL / 2 cells, a mouse lung adenocarcinoma cell line, were transplanted instead of B16F10 cells as a non-target tumor to form a tumor. That is, the same experiment as in 4-1 was performed except that the cancer cells forming the non-target tumor were changed from B16F10 cells to LL / 2 cells (see FIG. 16(A)).
[0089] The results are shown in Figure 16 (B) and (C). (B) shows the results for the targeted tumor, and (C) shows the results for the non-targeted tumor. Co-administration of HVJ-E and OX40 agonist antibody to melanoma cell tumors (target tumors) did not suppress the growth of lung cancer cell tumors (non-target tumors). These results demonstrated that the systemic antitumor effect induced by HVJ-E and OX40 agonist antibody is tumor cell type specific.
[0090] Example 10: Examination of the involvement of CD4 positive T cells and CD8 positive T cells in systemic antitumor effects We conducted experiments to clarify the role of CD4+ T cells and CD8+ T cells in the antitumor effect of HVJ-E and OX40 agonist antibody against non-target tumors.
[0091] B16F10 cells were transplanted into both sides of C57BL / 6N mice to form tumors (see FIG. 17(A)). HVJ-E and OX40 agonist antibodies were administered three times into the left tumor on days 0, 2, and 4. In addition, antibodies to eliminate CD4-positive T cells, antibodies to eliminate CD8-positive T cells, or control IgG were administered intraperitoneally on days -1, 0, 2, 4, and 6. The volumes of the target tumor (left side) and non-target tumor (right side) were recorded every 2 days from day 0 to day 14.
[0092] The results are shown in Figure 17 (B) and (C). (B) shows the results for targeted tumors, and (C) shows the results for non-targeted tumors. It was revealed that the anti-tumor effect against non-targeted tumors was weakened when CD8-positive T cells were removed, but the anti-tumor effect against non-targeted tumors was enhanced when CD4-positive T cells were removed. These results demonstrated that CD4-positive T cells control CD8-positive T cells to prevent the immune system from becoming overly activated. It was also found that the combined use of HVJ-E, OX40 agonist antibody, and CD4-positive T cell-depleting antibody can induce a strong anti-tumor effect against non-targeted tumors.
[0093] Example 11: Examination of systemic antitumor effect by combined use of apolipoprotein and OX40 agonist antibody B16F10 cells transfected with Tet GFP-Apol9a-Apol9b-Apod were transplanted into the left side of C57BL / 6N mice, and wild-type B16F10 cells were transplanted into the right side to form tumors (see Figure 18(A)). The administration schedule of doxycycline was as described above. OX40 agonist antibody or control IgG was administered into the left tumor three times on days 0, 2, and 4. The volumes of the target tumor (left side) and non-target tumor (right side) were recorded every two days from day 0 to day 14. Body weight was also measured on days 0, 4, 8, and 14.
[0094] The results are shown in Figure 18 (B), (C), and (D). (B) shows the results for body weight, (C) for the target tumor, and (D) for the non-target tumor. When apolipoproteins were expressed in the tumor by administration of doxycycline and OX40 agonist antibody was administered intratumorally, tumor growth was strongly suppressed not only in the target tumor but also in the non-target tumor. In addition, no weight loss was observed throughout the observation period, suggesting that no immune-related adverse events occurred.
[0095] Example 12: Examination of systemic antitumor effect by combined use of Irf7 and OX40 agonist antibody Tet GFP-Irf7-introduced B16F10 cells were transplanted into the left side of C57BL / 6N mice, and wild-type B16F10 cells were transplanted into the right side to form tumors (see FIG. 19(A)). As a control, Tet-GFP-introduced B16F10 cells were transplanted into the left side of C57BL / 6N mice, and wild-type B16F10 cells were transplanted into the right side to form tumors (see FIG. 20(A)). The administration schedule of doxycycline was as described above. OX40 agonist antibody or control IgG was administered into the left tumor three times on days 0, 2, and 4. The volumes of the target tumor (left side) and non-target tumor (right side) were recorded every two days from day 0 to day 14.
[0096] The results of using Tet GFP-Irf7-introduced B16F10 cells as target tumors are shown in Figure 19 (B) and (C), and the results of using Tet GFP-introduced B16F10 cells as target tumors are shown in Figure 20 (B) and (C). (B) shows the results of the target tumor, and (C) shows the results of the non-target tumor. When Irf7 was expressed in the tumor by doxycycline administration and OX40 agonist antibody was administered intratumorally, tumor growth was suppressed not only in the target tumor but also in the non-target tumor. On the other hand, when only GFP was expressed in the tumor by doxycycline administration and OX40 agonist antibody was administered in the tumor, tumor growth was not suppressed in either the target tumor or the non-target tumor. From these results, it was found that the growth inhibitory effect of non-target tumors can be exerted by expressing Irf7 in the tumor, which increases the expression of apolipoproteins downstream.
[0097] [Example 13: Examination of the systemic immunostimulatory effect by combined use of HVJ-E and OX40 agonist antibody] (1) Assessment of T cell numbers in target and non-target tumors B16F10 cells (wild type) were transplanted into both the left and right sides of C57BL / 6N mice to form tumors. Four groups were established: a group administered HVJ-E and an agonist antibody against the T cell costimulator OX40 (HVJE+OX40 group), a group administered HVJ-E and control IgG (HVJE+CtrlIgG group), a group administered PBS and an OX40 agonist antibody (PBS+OX40 group), and a group administered PBS and control IgG (PBS+CtrlIgG group). The doses described in the above [Experimental Method] were administered into the left tumor (target tumor) three times on days 0, 2, and 4. On days 10 and 11, the target tumor and non-target tumor (right tumor) were excised, and the number of CD4 positive T cells (CD45 / CD3 / CD4) and CD8 positive T cells (CD45 / CD3 / CD8) per 100,000 cells was measured by FACS (see Figure 21(A)).
[0098] The results are shown in Figure 21 (B) and (C). (B) shows the results for the target tumor, and (C) shows the results for the non-target tumor. The combined use of HVJ-E and OX40 agonist antibody significantly increased CD4-positive T cells and CD8-positive T cells not only in the target tumor but also in the non-target tumor. On the other hand, no increase in T cells was observed when HVJ-E or OX40 agonist antibody was administered alone.
[0099] (2) Assessment of T cell activation status in non-target cells The number of IFNγ-positive cells and Ki67-positive cells in Foxp3-negative CD4-positive T cells and CD8-positive T cells in non-target tumors in the HVJE+OX40 group and the HVJE+CtrlIgG group were measured by FACS. Ki67 is a cell proliferation marker.
[0100] The results are shown in Figure 22. The results are shown as the percentage (%) of IFNγ positive cells or Ki67 positive cells to all Foxp3 negative CD4 positive T cells, and the percentage (%) of IFNγ positive cells or Ki67 positive cells to all CD8 positive T cells. It was shown that the combined use of HVJ-E and OX40 agonist antibody significantly increased IFNγ expression in T cells of non-target tumors, and significantly enhanced cell proliferation.
[0101] Example 14: Examination of the systemic immunostimulatory effect of combined use of apolipoprotein and OX40 agonist antibody B16F10 cells transfected with Tet GFP-Apol9a-Apol9b-Apod were transplanted into the left side of C57BL / 6N mice, and wild-type B16F10 cells were transplanted into the right side to form tumors (see Figure 23(A)). The administration schedule of doxycycline was as described above. OX40 agonist antibody or control IgG was administered into the left tumor (target tumor) three times on days 0, 2, and 4. On day 14, the target tumor and non-target tumor (right tumor) were excised, and the number of IFNγ-positive cells, Ki67-positive cells, granzyme A-positive cells, and granzyme B-positive cells in CD4-positive T cells and CD8-positive T cells were measured by FACS. Granzymes A and B are enzymes that induce apoptosis of target cells.
[0102] The results are shown in Figure 23(B). The results are shown as the percentage (%) of positive cells for each index relative to the total CD4 positive T cells or total CD8 positive T cells. In the CD4 positive T cells and CD8 positive T cells of non-target tumors in the OX40 agonist antibody administration group, IFNγ expression was significantly increased compared to the control IgG administration group, indicating that cell proliferation was significantly enhanced. In addition, in the CD8 positive T cells of non-target tumors, granzyme A expression was significantly increased compared to the control IgG administration group.
[0103] Example 15: Examination of systemic antitumor and systemic immunostimulatory effects of combined use of apolipoprotein and OX40 agonist antibody Tet GFP-Apod-introduced B16F10 cells were transplanted into the left side of C57BL / 6N mice, and wild-type B16F10 cells were transplanted into the right side to form tumors (see Figure 24(A)). The administration schedule of doxycycline was as described above. OX40 agonist antibody or control IgG was administered into the left tumor (target tumor) three times on days 0, 2, and 4. The volumes of the target tumor (left side) and non-target tumor (right side) were recorded every two days from day 0 to day 14. On day 14, the target tumor and non-target tumor (right side tumor) were excised, and the number of CD4 positive T cells (CD45 / CD3 / CD4) and CD8 positive T cells (CD45 / CD3 / CD8) per 100,000 cells were measured by FACS.
[0104] The results of the antitumor effect are shown in Figure 24 (B) and (C). (B) shows the results for the target tumor, and (C) shows the results for the non-target tumor. When apolipoproteins were expressed in the tumor by administration of doxycycline and OX40 agonist antibody was administered intratumorally, tumor growth was strongly suppressed not only in the target tumor but also in the non-target tumor.
[0105] The results of the number of CD4 positive T cells and CD8 positive T cells are shown in Figure 25 (A) and (B). (A) is the result for the target tumor, and (B) is the result for the non-target tumor. When apolipoprotein was expressed and OX40 agonist antibody was administered intratumorally, the number of CD4 positive T cells and CD8 positive T cells increased significantly not only in the target tumor but also in the non-target tumor.
[0106] Example 16: Examination of systemic antitumor and systemic immunostimulatory effects by combined use of apolipoprotein and OX40 agonist antibody B16F10 cells (wild type) were implanted into both sides of C57BL / 6N mice to form tumors. Four groups were administered: 40μg of purified Apod protein and OX40 agonist antibody (Apod / OX40 group), 40μg of purified Apod protein and control IgG (Apod / CtrlIgG group), PBS and OX40 agonist antibody (PBS / OX40 group), and PBS and control IgG (PBS / CtrlIgG group). Tumors were administered into the left tumor (target tumor) five times on days 0, 2, 4, 6, and 8. The volumes of the target tumor (left) and non-target tumor (right) were recorded every two days from day 0 to day 14. On day 14, the target and non-target tumors were excised, and the numbers of CD4-positive T cells (CD45 / CD3 / CD4) and CD8-positive T cells (CD45 / CD3 / CD8) per 100,000 cells were measured by FACS.
[0107] The results of the antitumor effect are shown in Figure 26 (A) and (B). (A) shows the results for the target tumor, and (B) shows the results for the non-target tumor. When apolipoprotein and OX40 agonist antibody were administered intratumorally, tumor growth was strongly suppressed not only in the target tumor but also in the non-target tumor.
[0108] The results of the number of CD4 positive T cells and CD8 positive T cells are shown in Figure 27 (A) and (B). (A) is the result for the target tumor, and (B) is the result for the non-target tumor. When apolipoprotein and OX40 agonist antibody were administered intratumorally, the number of CD4 positive T cells and CD8 positive T cells increased significantly not only in the target tumor but also in the non-target tumor.
[0109] The present invention is not limited to the above-mentioned embodiments and examples, and various modifications are possible within the scope of the claims. The technical scope of the present invention also includes embodiments obtained by appropriately combining the technical means disclosed in the different embodiments. In addition, all academic documents and patent documents described in this specification are incorporated herein by reference.
Claims
1. A pharmaceutical for treating cancer, comprising as an active ingredient at least one apolipoprotein selected from the group consisting of apolipoproteins D, L1, L3, L9a and L9b.
2. A pharmaceutical for treating cancer, comprising at least one apolipoprotein selected from the group consisting of apolipoproteins D, L1, L3, L9a and L9b, and interferon regulatory factor 7 as active ingredients.
3. The pharmaceutical composition for cancer treatment according to claim 1 or 2, which is used in combination with an OX40 agonist antibody.
4. A drug for cancer treatment containing interferon regulatory factor 7 as an active ingredient, in combination with an OX40 agonist antibody.
5. A pharmaceutical for treating cancer, which contains Sendai virus envelope as an active ingredient and is used in combination with an OX40 agonist antibody or a 4-1BB agonist antibody.
6. The pharmaceutical composition for cancer treatment according to any one of claims 3 to 5, which has an effect of inhibiting the proliferation of non-target tumors.
7. The pharmaceutical composition for cancer treatment according to any one of claims 3 to 5, further comprising a CD4-positive T cell depleting antibody in combination therewith.
8. An immunostimulant comprising at least one active ingredient selected from the group consisting of an apolipoprotein, interferon regulatory factor 7, and Sendai virus envelope, and used in combination with a T-cell costimulatory factor agonist, wherein the apolipoprotein is at least one active ingredient selected from the group consisting of apolipoproteins D, L1, L3, L9a, and L9b, the T-cell costimulatory factor agonist combined with the apolipoprotein or interferon regulatory factor 7 is an OX40 agonist antibody, and the T-cell costimulatory factor agonist combined with the Sendai virus envelope is an OX40 agonist antibody or a 4-1BB agonist antibody.
9. The immunostimulant according to claim 8 , which is for topical administration.
10. The immunostimulant according to claim 8 or 9, further comprising a CD4 positive T cell depleting antibody in combination therewith.
11. A method for screening an anticancer substance, comprising the steps of: (1) contacting a test substance with cancer cells; (2) measuring the expression level of IRF7 in the cancer cells; and (3) comparing the obtained IRF7 expression level with the IRF7 expression level in the cancer cells not contacted with the test substance, and selecting a test substance that increases the expression level. The method according to claim 1, further comprising:
12. A method for screening an anticancer substance, comprising the steps of: (1) contacting a test substance with cancer cells; (2) measuring the expression level of an apolipoprotein in the cancer cells; and (3) comparing the obtained apolipoprotein expression level with the apolipoprotein expression level of the cancer cells not contacted with the test substance, and selecting a test substance that increases the expression level. Including, The method, wherein the apolipoprotein is at least one apolipoprotein selected from the group consisting of apolipoprotein D, L1, L3, L9a and L9b.
Citation Information
Patent Citations
Apolipoprotein C-I and application thereof in preparing drug for treating nephroblastoma
CN103880949A
Medical uses of apolipoprotein a and activators thereof
EP3594683A1
Method for inhibiting cell proliferation using apolipoprotein e
JP1996502730A
Method for treating solid tumors or lymphoid tumors by combination therapy
JP2018530624A
Anti-ICOS agonist antibodies and their uses
JP2020515239A
